AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23878109
Drug: Scutellaria lateriflora
RxNorm normalized name: Scutellaria lateriflora
DrugBank: Scutellaria lateriflora (DB14339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scutellaria lateriflora (350 mg)
Trial: 9704834
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 0.05% cream once daily
Trial: 9704834
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate 0.05% cream twice daily
Trial: 9704834
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FP and CB)
Trial: 9345395
Drug: 3 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Trial: 9345395
Drug: 9 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Trial: 2565767
Drug: Alpidem (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem (150 mg/day)
Trial: 348406
Drug: Hydrocortisone valerate
RxNorm normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone valerate cream (0.2 percent)
Trial: 348406
Drug: Fluorinated beta-methasone
RxNorm normalized name: beta-Methasone alcohol
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorinated beta-methasone valerate cream (0.1 percent)
Trial: 348406
Drug: Hydrocortisone cream
RxNorm normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone cream (0.1 percent)
Trial: 9348547
Drug: Medication-free phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication-free phase
Trial: 8406169
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ursodeoxycholic acid
Trial: 3465375
Drug: Intravenous Prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Prostaglandin F2-alpha
Trial: 3465375
Drug: Intramuscular Prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Prostaglandin F2-alpha
Trial: 30249630
Drug: Initial triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial triple combination therapy with metformin, dapagliflozin, and saxagliptin
Trial: 30249630
Drug: Conventional stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional stepwise add-on therapy
Trial: 26767508
Drug: 4 Pillars
RxNorm normalized name: BACCHARIS PILULARIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Pillars Immunization Toolkit, early delivery of donated vaccine, staff education, feedback on progress
Trial: 20697276
Drug: Gatifloxacin (0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (0.3% gatifloxacin ophthalmic solution)
Trial: 20697276
Drug: Moxifloxacin (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (0.5% moxifloxacin hydrochloride ophthalmic solution)
Trial: 18443573
Drug: D2 (4
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D2 (4 mg/1.25 mg)
Trial: 18443573
Drug: D1 (2
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 (2 mg/0.625 mg)
Trial: 1852179
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy (surgical treatment)
Trial: 31955956
Drug: Hypokalemia (<3.0mEq/L)
RxNorm normalized name: Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypokalemia (<3.0mEq/L)
Trial: 31955956
Drug: Hyperkalemia (>6.0mEq/L)
RxNorm normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyperkalemia (>6.0mEq/L)
Trial: 31955956
Drug: Normokalemia (3.5-5mEq/L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normokalemia (3.5-5mEq/L)
Trial: 28906561
Drug: Intravenous rolapitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rolapitant (166.5 mg)
Trial: 28906561
Drug: Oral rolapitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rolapitant (180 mg)
Trial: 19120077
Drug: Standard-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose tacrolimus (target trough levels >10 ng/mL) and corticosteroids; n = 183
Trial: 19120077
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2g/day, reduced-dose tacrolimus (target trough levels </=8 ng/mL), and corticosteroids; n = 170
Trial: 19120077
Drug: Daclizumab induction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab induction, MMF, reduced-dose tacrolimus delayed until the fifth day posttransplant, and corticosteroids; n = 172
Trial: 16881381
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone therapy (HT)
Trial: 16881381
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel
Trial: 16881381
Drug: Matrix patch
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix patch
Trial: 11342892
Drug: N-acetylcysteine, aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine, aspirin, and ranitidine
Trial: 7947564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (age and sex matched individuals without oral cancer)
Trial: 30724760
Drug: Medication-overuse headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-overuse headache (MOH) patients using simple analgesics
Trial: 30724760
Drug: Medication-overuse headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-overuse headache (MOH) patients using centrally acting analgesics
Trial: 30724760
Drug: Medication-overuse headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-overuse headache (MOH) patients classified as DSM-IV substance dependent
Trial: 21966393
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg/d; n = 105)
Trial: 21966393
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n = 111)
Trial: 18838842
Drug: Pre-exercise hyperhydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise hyperhydration (26 ml of water x kg body mass(‐1) with 1.2 g glycerol x kg body mass(‐1))
Trial: 11866251
Drug: Methadone dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone dose reduction with decrease instruction
Trial: 11866251
Drug: Methadone dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone dose decrease
Trial: 25556837
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance dose
Trial: 8948744
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine 4 mg and bupivacaine 0.125% 100 ml
Trial: 8948744
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCA) with morphine 30 mg and ketorolac 90 mg in 100 ml of saline
Trial: 15943220
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg once daily for 8 weeks
Trial: 15943220
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg once daily for 8 weeks
Trial: 16690590
Drug: Low folic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low folic acid diet (0 mg/kg)
Trial: 16690590
Drug: Basal folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal folic acid diet (2 mg/kg)
Trial: 16690590
Drug: High folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High folic acid diet (40 mg/kg)
Trial: 15364642
Drug: Aesculus hippocastanum
RxNorm normalized name: Aesculus hippocastanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aesculus hippocastanum tablets (Aesculaforce 50mg), taken twice daily for 8 weeks.
Trial: 29797436
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days)
Trial: 29797436
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days) and amoxicillin (AMX; 500 mg/TID for 14 days)
Trial: 27535654
Drug: Manual pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual pressure applied at the vaccination site for 10 seconds before injection
Trial: 27535654
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection technique without manual pressure
Trial: 24823599
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg, q.d.
Trial: 23839593
Drug: Program combining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program combining pre-authorization requirement and systematic post-prescription review of carbapenems
Trial: 14501599
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (10 mg/day testosterone cream)
Trial: 11103826
Drug: Psychological therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy, relaxation training, and stress management
Trial: 6146821
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg every evening
Trial: 30463520
Drug: Patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient treatment modality
Trial: 23185750
Drug: QM +
RxNorm normalized name: quinine sulfate Oral Tablet [QM-260]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QM + chemotherapy
Trial: 23185750
Drug: Pure chemotherapy
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure chemotherapy (control group)
Trial: 19858256
Drug: Levofloxacin 7
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 7 mg/kg body weight
Trial: 19858256
Drug: Levofloxacin 8
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 8 mg/kg twice a day
Trial: 19858256
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg and 750 mg in healthy adults
Trial: 16227840
Drug: Moxifloxacin hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop every 15 minutes for 4 doses before surgery (group 1)
Trial: 16227840
Drug: Moxifloxacin hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop 4 times per day on the day before surgery plus the same preoperative regimen as group 1 (group 2)
Trial: 12382950
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (1500 pulses ESWT at 0.12 mJ/mm2)
Trial: 9272102
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement at 0.024 mg/kg per day
Trial: 9272102
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement at 0.012 mg/kg per day
Trial: 9272102
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement (both doses)
Trial: 9272102
Drug: Patients continuing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continuing GH therapy
Trial: 8257527
Drug: Somatostatin analog
RxNorm normalized name: Somatostatin analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analog SMS 201-995 (SMS) at doses ranging from 0.8-2.2 micrograms/kg sc
Trial: 8257527
Drug: Somatostatin analog
RxNorm normalized name: Somatostatin analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analog SMS 201-995 (SMS) at standard doses of 1 microgram/kg sc
Trial: 3001518
Drug: Intranasal alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal alpha 2-interferon
Trial: 25940353
Drug: School-based scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based scheme for diagnosis and treatment of schistosomiasis mansoni
Trial: 25940353
Drug: Community-based scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based scheme for diagnosis and treatment of schistosomiasis mansoni
Trial: 25940353
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of positives for Schistosoma mansoni with praziquantel
Trial: 25940353
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of positives for soil-transmitted helminthes (STH) with mebendazole
Trial: 23080288
Drug: Hib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib plus MCC vaccine
Trial: 21134613
Drug: Collagenase (0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase (0.58 mg)
Trial: 18197912
Drug: IL-8 measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-8 measurement in pleural fluid at a cutoff value of 1000 pg/mL
Trial: 18197912
Drug: CRP measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP measurement in pleural fluid at a cutoff value of 80 mg/L
Trial: 17313855
Drug: PEG-rhG-CSF 100
RxNorm normalized name: PEG-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF 100 microg/kg (single subcutaneous injection on day 3)
Trial: 17313855
Drug: rhG-CSF 5
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhG-CSF 5 microg x kg(‐1) x d(‐1) (daily subcutaneous injection starting on day 3 for 14 days)
Trial: 14728105
Drug: Baclofen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (20 mg t.i.d.)
Trial: 11022077
Drug: Increased Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased Lp(a) level (>30 mg/dL)
Trial: 8828247
Drug: medication only,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication only, no contingencies
Trial: 1441947
Drug: Growth hormone-loaded
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone-loaded PMMA (20 mg of growth hormone)
Trial: 1441947
Drug: Cemented or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented or cementless hip replacement without added growth hormone (Control)
Trial: 15936468
Drug: Glimepiride (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (doses equivalent to gliclazide 40 mg = glimepiride 1 mg, glibenclamide 2.5 mg = glimepiride 2 mg)
Trial: 15936468
Drug: Conventional SU
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional SU (gliclazide or glibenclamide, no change in treatment)
Trial: 8874326
Drug: IFN alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha 2a (9 million IU) subcutaneously three times weekly with 5‐FU (750 mg/m2/d) by continuous intravenous infusion on days 1 to 5 and then weekly IV bolus at the same dose
Trial: 8874326
Drug: 5‐FU alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU alone at the same dose schedule
Trial: 1642918
Drug: Crystalloid preload
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid preload 20 ml kg‐1 over 10 min
Trial: 1642918
Drug: Crystalloid preload
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid preload 20 ml kg‐1 over 20 min
Trial: 24650832
Drug: Behavioral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral placebo treatment (BPT)
Trial: 16531614
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg)
Trial: 16531614
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg) + Vitamin B6 (40 mg)
Trial: 10694782
Drug: Cocoa butter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa butter (30.7 g/d) consumed in the form of black chocolate
Trial: 9380281
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, single oral dose)
Trial: 8096475
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oxytocin infusion)
Trial: 2864051
Drug: Nadolol 80
RxNorm normalized name: nadolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 80 mg once daily
Trial: 28105902
Drug: Adjunctive porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive porcine small intestine submucosa (SIS; Oasis Ultra)
Trial: 24162940
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibuprofen and paracetamol
Trial: 19466669
Drug: Ephedrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (50 mg taken 1 hour prior to sexual activity)
Trial: 19466669
Drug: SSRIs (sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (sertraline, paroxetine)
Trial: 19466669
Drug: SSRIs (fluoxetine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (fluoxetine)
Trial: 15199624
Drug: SQNYCH combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQNYCH combined with chemotherapy
Trial: 15199624
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine only
Trial: 336002
Drug: L-5-hydroxytryptophan (L-5-HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L-5-HTP) in combination with Benzerazide
Trial: 26247351
Drug: Micro-capsules containing
RxNorm normalized name: fenofibrate Oral Capsule [Lipantil Micro]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-capsules containing menthol/PCL
Trial: 22975664
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel plus cilostazol (intensification group, n = 72)
Trial: 22975664
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (control group, n = 74)
Trial: 22975664
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel plus cilostazol (intensification group)
Trial: 19558562
Drug: 5-ASA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA (1.5 g for 1 year)
Trial: 16122956
Drug: Valdecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (40 mg) given orally for 4 days prior to oesophageal acid infusion
Trial: 16122956
Drug: IV Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IV Parecoxib (40 mg) given 120 min after oesophageal acid infusion
Trial: 16122956
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given orally for 4 days prior to oesophageal acid infusion